Metal-organic compounds: A new approach for drug discovery: N1-(4-methyl-2-pyridyl)-2,3,6-trimethoxybenzamide copper(II) complex as an inhibitor of human immunodeficiency virus 1 protease

Biochemical Pharmacology

Volumn 63, Issue 10, 2002, Pages 1863-1873

  Lebon, Florence ^a   Boggetto, Nicole ^b   Ledecq, Marie ^a   Durant, François ^a   Benatallah, Zohra ^c   Sicsic, Sames ^c   Lapouyade, René ^d   Kahn, Olivier ^d   Mouithys Mickalad, Ange ^e   Deby Dupont, Ginette ^e   Reboud Ravaux, Micheèle ^b  

^a UNIVERSITY OF NAMUR   (Belgium)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS SUD   (France)

^d INST CHIM MATIERE COND BORDEAUX   (France)

^e UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

AIDS; Antiprotease; Copper complexes; HIV 1 protease; Inhibition; Metal organic complexes

Indexed keywords

AMIDE; CHELATING AGENT; COPPER COMPLEX; COPPER ION; LIGAND; METAL; N1 (4 METHYL 2 PYRIDYL) 2,3,6 TRIMETHOXYBENZAMIDE; N2 (2 CYCLOHEXYL) 2 QUINOLINECARBOXAMIDE; N2 (2 METHOXYBENZYL) 2 QUINOLINECARBOXAMIDE; N2 (2 METHOXYBENZYL) 6 PHENYL 1,3 OXAZINANE 2 CARBOXAMIDE; N2 BENZYL 2 QUINOLINECARBOXAMIDE; OXAZINANE CARBOXAMIDE; PROTEINASE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CATALYST; DRUG INHIBITION; DRUG TARGETING; ENZYMATIC ASSAY; ENZYME SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL;

BENZAMIDES; DRUG DESIGN; ELECTRON SPIN RESONANCE SPECTROSCOPY; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; MODELS, MOLECULAR; ORGANOMETALLIC COMPOUNDS; PYRIDINES;

EID: 0037094449     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)00918-8     Document Type: Article

References (33)

1. Targeting HIV-1 protease: A test of drug-design methodologies
2. HIV protease inhibitors
3. HIV-1 protease inhibitors. A review for clinicians
4. Approaches to the design of effective HIV-1 protease inhibitors
5. Lipopeptides as dimerisation inhibitors
6. Design, synthesis and evaluation of conformationaly constrained tongs, new inhibitors of HIV-1 protease dimerisation
7. HIV-protease inhibitors
8. Recent developments in HIV protease inhibitor therapy
9. Synthesis and structural analysis of copper(II) pyridineamide complexes as HIV-1 protease inhibitors
10. De novo drug design of a new copper chelate molecule acting as HIV-1 protease inhibitor
11. Inorganic chemistry and drug design
12. Metal complexes as enzyme inhibitors
13. Co-ordination chemistry of metallodrugs: Insights into biological speciation from NMR spectroscopy
14. Design of potent selective zinc-mediated serine protease inhibitors
15. A novel approach to serine protease inhibition: Kinetic characterisation of inhibitors whose potencies and selectivities are dramatically enhanced by zinc(II)
16. Specific inhibition of HIV-1 protease by boronated porphyrins
17. 1+
18. Synthesis of N-glyoxylyl peptides and their in vitro evaluation as HIV-1 protease inhibitors
19. Studies on Wallach's imidazole synthesis
20. Monoamine oxidase based on 2-, 4-, and 8-substituted quinolines
21. Studies on monoamine oxidase inhibitors. VII. Derivatives of quinolinecarboxylic acids
22. A facile convenient and selective homolytic carbamoylation of heteroaromatic bases
23. Purification, assay and kinetic features of HIV-1 protease
24. 6-Substituted 2-oxo-2H-1-benzopyran-3-carboxylic acid as a core structure for specific inhibitors of human leukocyte elastase
25. Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer
26. Design, activity, and 2.8 Å crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease
27. A priori prediction of activity for HIV-1 protease inhibitors employing energy minimisation in the active site
28. Copper inhibits the protease from human immunodeficiency virus 1 by both cysteine-dependant and cysteine-independent mechanisms
29. Reactivity of cysteine residues in the protease from human immunodeficiency virus: Identification of a surface-exposed region which affects enzyme function
30. The DNA-bound orientation of Cu(II)-Xaa-Gly-His metallopeptides
31. On the size of the active site in proteases I